Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma

Table 1 Clinical characteristics

Characteristic	All Patients (N = 172)		HBsAg and HBcAb Negative (n = 119)		HBsAg or HBcAb Positive (n = 53)		P
	No.	%	No.	%	No.	%	P
Age, years
Median (range)	58 (18–85)		57 (18–85)		62 (32–85)		0.02
Age groups, years
< 60	96	56	75	63	21	40	0.004
≥ 60	76	44	44	37	32	60
Sex							0.17
Male	95	55	62	52	33	62
Female	77	45	57	48	20	38
Ann Arbor stage
I	10	6	8	7	2	4	0.60
II	42	24	31	26	11	21
III	20	12	12	10	8	15
IV	100	58	68	57	32	60
B symptoms
No	82	48	58	51	24	45	0.67
Yes	90	52	61	49	29	55
Performance status 2–4	84	49	53	45	31	58	021
Extranodal
No	73	42	52	44	21	40	0.61
Yes	99	58	67	56	32	60
Serum LDH > Normal International prognostic index
Low	62	38	46	39	15	28	0.10
Low-intermediate	57	35	35	29	11	21
High-intermediate	30	18	23	19	14	26
High	15	9	15	13	13	24
Liver cirrhosis
No	170	99	118	99	52	98	0.55
Yes	2	1	1	1	1	2
Baseline liver function
ALT> UNL	14	8	10	8	4	8	0.78
AST > UNL	8	5	6	5	2	4	0.53
Bilirubin >UNL	6	3.5	5	4	1	2	0.39
Type of prophylaxis
NO	132	77	119	100	13	25
Entecavir	26	15	0	0	26	49
Lamivudine	14	8	0	0	14	26	0.00
Chemotherapy
R-CHOP	153	89	124	106	89	89	0.39
R-CVP	12	7	14	6	5	11
R-CEOP	3	2	2	3	3	0
R-EPOCH	4	2	0	4	3	8
Consolidation radiotherapy
Yes	17	10	12	10	5	9	0.89
No	155	90	107	90	48	91
No. of cycles
Median	6		6		6		0.40
Range	1–11		3–11		1–8

ISSN: 1750-9378